Oral Risperidone Equivalent for 25 mg IM Injection Every 2 Weeks
For a patient receiving risperidone long-acting injection 25 mg every 14 days, the equivalent oral dose is 3 mg/day or less. 1, 2
FDA-Approved Conversion Guidelines
The FDA label for risperidone extended-release injectable suspension does not provide a direct conversion table, but clinical trial data establish the relationship between oral and injectable formulations. 1
- Patients on oral risperidone ≤3 mg/day should receive 25 mg IM every 2 weeks 2
- Patients on oral risperidone >3 mg/day but ≤5 mg/day should receive 37.5 mg IM every 2 weeks 2
- Patients on oral risperidone >5 mg/day should receive 50 mg IM every 2 weeks 2
Pharmacokinetic Considerations
Working backward from these conversion ratios, a patient receiving 25 mg IM every 2 weeks is receiving the equivalent of approximately 2–3 mg/day oral risperidone. 2
- The long-acting formulation provides steady-state plasma concentrations after the fourth injection (approximately 8 weeks), with significant release beginning 3 weeks after the first injection 1, 3
- Plasma active moiety (risperidone plus 9-hydroxyrisperidone) levels at steady state are bioequivalent between the 25 mg IM formulation and corresponding oral doses 4
- The injectable formulation causes less plasma concentration fluctuation than oral dosing, which may improve tolerability 3
Critical Conversion Pitfalls
If converting FROM 25 mg IM TO oral risperidone:
- Start oral risperidone 2–3 mg/day immediately when discontinuing the injection 2
- The last injection will continue releasing drug for 7–8 weeks after administration, so overlap is not necessary 1, 3
- Monitor for symptom recurrence during the transition period, as elimination is gradual 4
If converting FROM oral TO 25 mg IM:
- Continue oral risperidone (or another antipsychotic) for 3 weeks after the first injection to maintain therapeutic levels until the main release phase begins 1
- The 25 mg IM dose is appropriate for patients previously stable on oral risperidone ≤3 mg/day 2
Special Population Adjustments
- Elderly patients: The recommended dose is 25 mg IM every 2 weeks with 3-week oral supplementation after the first injection 1
- Renal or hepatic impairment: Patients should tolerate oral risperidone 2 mg/day before initiating 25 mg IM; alternatively, consider starting at 12.5 mg IM (though efficacy at this dose is not established) 1
Monitoring During Conversion
- Extrapyramidal symptoms (EPS) can occur even at low doses equivalent to 2 mg/day oral risperidone 5
- The long-acting formulation demonstrated reduced EPS compared to equivalent oral doses in clinical trials, with lower Simpson-Angus Scale scores and reduced prolactin levels 2
- Assess for symptom control at 4-week intervals, as upward dose adjustments should not occur more frequently than every 4 weeks 1